Anthony DiGiandomenico - 10 Oct 2025 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Director
Signature
/s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
10 Oct 2025
Net transactions value
+$1,500,010
Form type
4
Filing time
15 Oct 2025, 21:54:17 UTC
Previous filing
01 Jul 2025
Next filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DIGIANDOMENICO ANTHONY Director C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR /s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact 15 Oct 2025 0001083544

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NDRA Common Stock Award $500,003 +70,822 +1301% $7.06 76,265 10 Oct 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NDRA Warrants Award $1,000,007 +141,644 $7.06 141,644 10 Oct 2025 Common Stock 141,644 $6.81 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.
F2 Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock.
F3 Includes unvested restricted stock units.